Summary The disposition of 5-fluorouracil (FUra) was studied in 19 colorectal cancer patients dunrng treatment with FUra and high-dose leucovorin (LV) with or without interferon x2a (IFN-a). All 
inconsistent with previous reports of a reduced rate of FUra elimination at higher IFN-c doses. suggest that any clinical effect of this moderate dose of IFN-a on FUra toxicity or activity is due to modulation at target cells. not to pharmacokinetic interaction.
Recent years have seen intense efforts to improve the activity of the pyrimidine analogue 5-fluorouracil (FUra) in the treatment of colorectal cancer and other solid tumours. Strategies have included novel administration routes and schedules (e.g. hepatic artery infusion, protracted venous infusion) and the exploitation of biochemical interactions with other drugs (e.g. leucovorin; PALA).
Interferons (IFNs), though they have no useful singleagent activity against colorectal cancer, nonetheless display synergistic cytotoxic interactions with FUra against certain human colorectal cancer models in vitro and in vivo (reviewed by Wadler & Schwartz. 1990) . A number of possible mechanisms of interaction have been proposed, including (with different interferons in different tumour models) stimulation by IFN of the metabolic pathway(s) leading to FUra activation (Schwartz et al., 1992) , inhibition by IFN of adaptive up-regulation of one of FUra's targets, thymidylate synthase (Chu et al., 1990; Seymour et al., 1992) , and enhancement by IFN of FUra-induced DNA breaks (Houghton et al.. 1993) . Clinical interest in the FUra,IFN-a combination was stimulated by a promising phase II trial of FUra and IFN-a in patients with colorectal cancer (Wadler & Wiernik, 1990) , and although attempts to repeat this study have met with lower response rates there is still a suggestion of a degree of clinical interaction between the two agents. The modulatory effect of IFN appears. in vitro, to be complementary to that of leucovorin (LV) (Houghton et al., 1991) , on which basis several groups are investigating 'double modulation' in the clinic, using FUra LV IFN-a combinations.
In addition to biochemical interactions at the target cell demonstrable in vitro, it has been suggested that. in vivo, the systemic pharmacokinetics of FUra is affected by concurrent administration of IFN-a. The results from different studies are conflicting: some report that IFN-a reduces the rate of FUra elimination. with correspondingly increased plasma concentrations and area under the concentration-time curve (AUC) (Grem et al., 1991; Danhauser et al.. 1993) . but others show no such effect (Kreuser et al.. 1992; Pittman et al., 1993; Sparano et al., 1993 The models are shown in schematic form in Figure 1 . Model (c) proved best overall, giving the optimum AIC in 10 of the 20 data sets, and second optimum for the remaining sets. It was therefore selected as the optimum model for the study and applied to all data sets for comparative analysis.
Statistical analysis
Statistical calculations were performed using MiniTab software. The normality of distribution of each pharmacokinetic variable was tested using the Shapiro-Wilk method. Among each of the two patient groups there was one 'outlier', identified as a value lying more than five standard deviations from the mean; in one case abnormally high volume of distribution (Vd) study. These two patients' data were excluded from the analysis in their entirety. Following this, comparison of parametric variables between the two groups of patients was made using the two-(independent) sample t-test. The effects of renal function, alkaline phosphatase and aspartate transaminase on pharmacokinetic parameters were each assessed using two-stage regression, correcting for the effect of treatment.
Results
Plasma FUra fell during the 60 min after bolus injection. then reached steady-state plasma concentration after 1.5-2 h of FUra infusion. Visual comparison of the geometric (logtransformed) mean data curves in Figure 2 shows that there is no substantial difference in FUra plasma levels between those patients receiving FUra V alone and those also receiving IFN-a. Mean total AUCO h,h, calculated using the linear trapezoidal method. is 1 16 JLM h for patients receiving FUra, LV alone and 125 JIM h for those also receiving IFN-a (P = 0.38). No consistent circadian rhythm was noted during the infusion phase. although the timing of samples was not selected to examine this phenomenon.
Model selection
The data show clear evidence of the non-linear disposition of FUra. The fall in plasma [FUra] during the first hour appears to follow a simple first-order exponential ( Figure 2) ; however, in every case there is wide disparity between the apparent rate of FUra clearance during this phase (566 ± 124 ml min-', mean ± s.d.) and the subsequent rate of FUra receiving FUra LV alone (0. n = 9) or with interferon (0. n = 9). Dotted lines are computer fits to these mean data. using the one-compartment linear + non-linear model illustrated in Table I clearance during steady-state infusion (1 717 ± 410 ml min ') Consequently. it is impossible to describe the data using a linear pharmacokinetic model. Figure 1 shows the six models tested using MAICE. as described in the Patients and methods section. In 10 of the 20 patients' data sets, model (c) 
Coefficient of difference of more than 18% and 22% respectively in these two parameters. Using partial area predictions, the linear elimination route accounts for >90% of the total drug clearance during the initial hour after FUra bolus. However. the non-linear route accounts for >55% of total clearance during the steady-state infusion.
Organ function Two-step regression was used to assess the effect of organ function on each of the pharmacokinetic parameters after correction for any effect of interferon. No significant correlations were found for serum alkaline phosphatase, serum aspartate transaminase or estimated creatinine clearance (using the formula of Cockcroft & Gault, 1976 With these reservations about the interpretation of parameters in the mathematical model used in this study, it might nonetheless be expected that changes in DPD activity would be primarily reflected as changes in the V,n,. In a recent study, Yee et al. (1992) found that DPD activity in patients' peripheral blood mononuclear cells fell by 50% after 4 days of IFN-a treatment. In the current study, no statistically significant difference in Vm,,,, was found, although the wide variability of this parameter means that a reduction of up to 48% could have been missed.
Previous studies of FUra, 'IFN-a pharmacokinetic interaction have yielded inconsistent results (see Table III ). All have used a paired cycle design, measuring plasma levels during FUra (or FUra,'LV) treatment, then adding IFN-a and resampling. This has the advantage of correcting for interpatient variability, but may introduce systematic error when treatments are always given in the same order. The studies have involved either bolus or infusional regimens, not both, and have assumed linear kinetics, deriving values for apparent plasma clearance (Cl) and apparent half life.
Two studies involve bolus FUra regimens. Grem et al. (1991) measured the kinetics of bolus FUra (with high-dose LV) before and after IFN-a2a at 3, 5 and 10 MU m-2 day-'. and reported a significant reduction of 25% in FUra clearance at the highest IFN--x dose. The results of Schuiller et al. (1992) are provocative: bolus FUra kinetics was measured in ten patients, first on FUra alone, then on FUra with IFNa2b and finally on triple therapy including high-dose LV. A linear two-compartment model was applied, and the authors found significantly decreased mean FUra clearance and increased mean AUC for FUra/'IFN-a compared with FUra alone. These changes appeared to be reversed when LV was introduced, leading to postulation that IFN-a decreases FUra's metabolic clearance and that its effect is negated by leucovorin. However, the inter-patient variability was greater for FUra/IFN-a than for the other data sets, with three patients having end-of-bolus plasma levels 2-3 times greater than the median. In the presence of non-linearity, this may have produced artefactually low values for FUra 'clearance': the conclusion of the study may have been different had an appropriate non-linear model been used.
Turning to infusional regimens, an early abstract report of dramatic elevation of FUra levels within 1 h of administering IFN-a2b has yet to be published in full (Lindley et al.. 1990 ). More recently Danhauser et al. (1993) . assuming that steadystate FUra plasma concentration had been reached after 50 min (five 'half-lives') of FUra continuous infusion, calculated Cl%5 from a single sample then introduced after 16-21 h. There was a statistically significant decrease in C 1S after adding IFN-a; however the complete lack of IFN-a dose relationship over the range 0.1-15.0 MU m' suggests that the difference may have been caused by the timing of samples rather than by IFN-a. Sparano et al. (1993) made a more thorough assessment of steady-state kinetics, using at least seven samples over 48 h. before introducing IFN-a2a. Care was taken to correct for diurnal vanration in FUra kinetics by performing cosinor analysis before and after IFN--m addition. No effect of IFN-x on FUra kinetics was seen. Similarly, Pittman et al. (1993) . in the only study to use a random-order crossover design. found no effect of IFN-a2a on [FUraL in 26 patients. Kreuser et al. (1992) . also using multiple samples, measured drug levels during a 4 h infusion of 500 mg m-2 FUra before and after the addition of again. no difference was found.
In conclusion IFN-a. at 6 MU on alternate days. has no significant effect on the pharmacokinetics of FUra. The current study has the advantages of exaamining both bolus and infusional phases of FUra administration, and of using a non-linear pharmacokinetic model which avoids the artefactual variations in apparent clearance which arise with the inappropriate use of linear modelling. Review of the literature suggests that, at higher doses of IFN-a around 10 MU m-2 day-', FUra elimination may be reduced, probably through decreased DPD activity. However, some of the studies which have suggested an effect should be interpreted with reservation, and there is no conclusive published evidence for a pharmacokinetic interaction at lower doses of IFN-a.
